Northern Trust
VRNA

Northern Trust’s Verona Pharma VRNA Stock Holding History

Northern Trust’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,800
Closed -$362K – 4506
2024
Q4 		$362K Buy
+7,800
New +$293K ﹤0.01% 3767

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust's VRNA Position: Q1 2025 in Review

Northern Trust sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 7,800 shares — an estimated $362K sold.

Northern Trust first reported a position in VRNA in Q4 2024 and held it in 1 quarter. The position peaked at $362K in Q4 2024. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

  • Northern Trust reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
  • Northern Trust sold 7,800 Verona Pharma shares in Q1 2025, an estimated $362K.
  • Northern Trust first reported a position in Verona Pharma in Q4 2024 and held it in 1 quarter.
  • Northern Trust's Verona Pharma position peaked at $362K in Q4 2024.
  • 258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.